World Journal of Pharmaceutical Sciences

A NOVEL RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION AND ESTIMATION OF LAMIVUDINE AND TENOFOVIR DRUG WITH ITS BULK FORM AND TABLET FORMULATION

Manasa Kola — 2024-09-26

A straight forward and robust technique was devised to simultaneously estimate the concentrations of Lamivudine and Tenofovir in tablet dose form. The chromatogram was passed through an Inertsil C18 150 mm (4.6 x 150mm, 5μm) Mobile phase that included a Buffer (Ammonium Acetate) consisting of 90% Methanol. 10% of the buffer was pushed through the column at a flux rate of 1.2 ml/min. Thermal condition was regulated at 26°C. The selected optimised wavelength was 245.0 nm. The observed retention times for Lamivudine and Tenofovir were 2.247 minutes and 2.879 minutes, respectively. The relative standard deviation (RSD) obtained for Lamivudine and Tenofovir were 0.5 and 0.7 correspondingly. %The recoveries achieved for Lamivudine and Tenofovir were 101.07% and 99.98% respectively. The linear optical density (LOD) and limit of quantification (LOQ) values derived from the regression equations of Lamivudine and Tenofovir were 0.18, 0.19, and 0.54, 0.56 correspondingly. There are two regression equations for Lamivudine: y = 8523.9x + 11099 and y = 12735x + 2600.A reduction in retention times and a corresponding drop in run time made the devised approach easy and cost-effective for use in routine quality control tests in industries

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN AND VILDAGLIPTIN BY USING RP-HPLC

Rasapelly Ramesh Kumar — 2024-09-20

This study presents a novel approach for the concurrent quantification of Dapagliflozin and Vildagliptin in tablet form. Chromatogram was analysed using a Discovery C18 column (4.6 x 150mm, 5μm). A mobile phase consisting of Acetonitrile and Na2hpo4 prepared in a 70:30 ratio was passed down the column at a flow rate of 0.8 ml/min. The solution employed in this technique is a phosphate buffer, and the pH is modified to 5.2 by the addition of 0.1% Formic acid. The temperature was kept constant at 30°C. The selected optimised wavelength was 220 nm. The observed retention times for Dapagliflozin and Vildagliptin were 2.307 minutes and 2.865 minutes, respectively. The relative standard deviation (RSD) of Dapagliflozin and Vildagliptin were determined to be 0.9 and 0.7 correspondingly. The observed recovery rates for Dapagliflozin and Vildagliptin were 100.41% and 99.94% respectively. The limit of detection (LOD) and limit of quantification (LOQ) values derived from the regression equations of Dapagliflozin and Vildagliptin were 0.02, 0.07, and 0.24, 0.72 correspondingly. The regression equation for Dapagliflozin is provided as y = 42540x + 1488.4. Furthermore, the equation y = 38485x + 2186.5 of Vildagliptin. By reducing retention times and run time, the new approach proved to be easy and cost-effective for use in routine quality control tests in industries.

STABILITY INDICATING DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR RP-HPLC METHOD

Vineela Yarasingi — 2024-09-26

Sofosbuvir and Velpatasvir were developed with Std Discovery 250 x 4.6 mm, 5m. Buffer-containing MP OPA :MeCN in the 55:45 ratio was poured across the column at 1 ml/min. This procedure employed 0.1% Perchloric acid buffer. The temperature was 30°C. Optimised wavelength was 230 nm. Sofosbuvir and Velpatasvir had 2.146 and 2.770 min retention times. Sofosbuvir and Velpatasvir had 0.4 and 0.5 RSD. %Recovery was 100.09% for Sofosbuvir and 100.62% for Velpatasvir. Sofosbuvir and Velpatasvir regression equations yielded LOD, LOQ values of 0.24, 0.73, and 0.15, 0.45. The regression equations for Sofosbuvir and Velpatasvir are y = 91520.x + 1773.9 and y = 179637x + 22360, respectively. Reduced retention and run time for better method development.

STABILITY INDICATING DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF LAMIVUDINE AND DOLUTEGRAVIR RP-HPLC METHOD

Addagetala Sowjanya — 2024-09-26

Lamivudine and Dolutegravir were developed with Std Discovery 250 x 4.6 mm, 5m. Buffer-containing MP OPA :MeCN in the 55:45 ratio was poured across the column at 1 ml/min. This procedure employed 0.1% Perchloric acid buffer. The temperature was 30°C. Optimised wavelength was 230 nm. Lamivudine and Dolutegravir had 2.146 and 2.770 min retention times. Lamivudine and Dolutegravir had 0.4 and 0.5 RSD. %Recovery was 100.09% for Lamivudine and 100.62% for Dolutegravir. Lamivudine and Dolutegravir regression equations yielded LOD, LOQ values of 0.24, 0.73, and 0.15, 0.45. The regression equations for Lamivudine and Dolutegravir are y = 91520.x + 1773.9 and y = 179637x + 22360, respectively. Reduced retention and run time for better method development.

METHOD DEVELOPMENT AND VALIDATION OF TELMISARTAN BY USING RP-HPLC

P.R. Sudha Rani — 2024-09-09

A straightforward, reliable reverse phase RP-HPLC technique has been devised and verified for the quantification of Telmisartan in both bulk and pharmaceutical dose forms. Chromotography was estimated by Stationary phase is STD Ascentis C18 (250mm×4.6mm 5μm) for elutant separation, and the Mobile phase is 0.01N Kh2Po4 and Acetonitrile in the ratio of 8:2 at a flow rate 0.5ml/min was maintained, maximum wave length at 296.0 nm, Temperature was set to 30oC. The average retention time of Telmisartan were found to be 5.100 min respectively. By injecting the standard six times, the system suitability characteristics were evaluated, and the results were significantly below the acceptance requirement (Limit of less than 2). A linearity analysis was conducted between 25% and 150% levels, and the R2 value was found to be 0.999. Several validation criteria, including precision, accuracy, LOD, LOQ, and robustness, were determined to be within accepted limits. % recovery was obtained as 99.49% for Telmisartan respectively. The approach was discovered to be simple, accurate, sensitive, quick, and cost effective, with a runtime of less than 30 minutes. In practice, this approach may also be used to determine assay in tablet formulation.

A VALIDATED STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN, METFORMIN AND SAXAGLIPTIN IN BULK IN PHARMACEUTICAL ORAL DOSAGE FORMS.

Koppula Sravani — 2024-09-26

Metformin, Dapagliflozin, and Saxagliptin in solid dose form were estimated simultaneously using a simple, accurate, and exact approach. The chromatogram was conducted on an Agilent C18 150x4.6mm, 5mm. A mobile phase comprising acetonitrile and 0.01N Kh2Po4 in a 70:30 v/v ratio was injected through the column at a flow rate of 1.2mL/min. Buffer pH was adjusted to 3.5pH using Ortho Phosphoric Acid. The temperature was kept at 26 °C. The optimal wavelength for Metformin, Dapagliflozin, and Saxagliptin was 238.0 nm. Metformin, dapagliflozin, and saxagliptin had retention times of 3.598, 2.827, and 3.209 minutes, respectively. The %RSD of system accuracy for Metformin, Dapagliflozin, and Saxagliptin were determined to be 0.7, 0.4, and 0.6, respectively. The %RSD of method precision for Metformin, Dapagliflozin, and Saxagliptin were determined to be 0.7, 0.9, and 0.4, respectively. Metformin, Dapagliflozin, and Saxagliptin showed percentage recovery rates of 100.03%, 100.23%, and 99.64%, respectively. LOD values are derived using regression models for Metformin, Dapagliflozin, and Saxagliptin. The LOQ values for Metformin, Dapagliflozin, and Saxagliptin were 1.62 μg/ml, 0.12 μg/ml, and 0.05 μg/ml, respectively, based on regression models. The regression equation for Metformin was y = 5641.2x + 8389.3. Dapagliflozin was y = 6070.3x + 132, whereas Saxagliptin was y = 5843.6x + 75.1. Retention durations are reduced, therefore the method devised was easy and cost-effective, and it may be used in frequent quality control tests in industries.

PHARMACOECONOMIC EVALUATION OF VANCOMYCIN AND TEICOPLANIN

M. Indhu Priya Dharshini — 2024-09-09

Teicoplanin and vancomycin are antibiotics widely prescribed for the treatment of Gram-positive bacterial infections. This review presents a pharmacoeconomic evaluation comparing the efficacy and cost-effectiveness of these two antibiotics. Clinical studies indicate that teicoplanin demonstrates superior efficacy in treating a range of Gram-positive infections, with higher cure rates and fewer adverse effects compared to vancomycin. Additionally, teicoplanin's pharmacokinetic properties allow for less frequent dosing, enhancing patient compliance and reducing hospital resource utilization. Economically, teicoplanin proves to be more cost-effective due to its lower overall treatment costs, including reduced hospitalization and monitoring expenses. These findings suggest that teicoplanin offers a more effective and economically advantageous option over vancomycin for the management of Gram-positive infections. This review underscores the importance of considering both clinical outcomes and economic factors in antibiotic selection to optimize healthcare resources and patient care.

ROLE OF SERUM APLEIN AND NITRIC OXIDE IN PRIMARY HYPERTENSION PATIENTS

P. Lakshmi Priyanka, — 2024-09-20

A frequent health problem that aggravates renal problems and other cardiovascular illnesses is hypertension. The significance of serum apelin and nitric oxide in controlling blood pressure and endothelial function has been identified by recent research. An endogenous peptide called apelin has been linked to cardiovascular homeostasis and has been demonstrated in hypertensive individuals to positively correlate with blood pressure levels. Increased apelin levels in the serum are frequently linked to hypertension and related side effects, including microalbuminuria.

ROLE OF SERUM APLEIN AND NITRIC OXIDE IN PRIMARY HYPERTENSION PATIENTS

P. Lakshmi Priyanka — 2024-09-26

Treatments Of Periodontitis : A Review Of Non Surgical Treatments to Surgical Treatments with Recent Advances

Jyoti Talageri — 2024-09-09

Periodontal disorders are pathological problems characterized by infection or inflammation of the periodontium, which is the connective tissue that provides support for the teeth. This condition is a common illness affecting over 40 percent of adults in the USA. Its most serious form approximately 11% prevalent worldwide. Advanced cases of periodontitis results in the loss of teeth and decline in life quality. A precise assessment, an elimination of underlying reasons, and the mitigation of modifiable danger indicators are the key elements for successful periodontal prevention and therapy. For evaluate, treat, and manage periodontal disease the pitiful attempt is made to incorporate certain non surgical to surgical with recent advances in treatment of periodontitis. The treatments include, non surgical home care review, scaling and root planning, prescription antibiotic treatment dental bacteria, bacterial invasion, bone regeneration: anabolic agents , effectiveness of propolis , herbal approaches, modulation and treatment of periodontal disease, surgeries , new inventions , current developments in therapeutic periodontal assessment and periodontal therapy techniques for Periodontal disorders.